Gastrointestinal Flowcharts

Revised: January 2, 2009

Colorectal Metastatic

Previously Untreated

VICC GI 0809
A Randomized, Placebo-Controlled Phase II Study of GDC-0449 (Systemic Hedgehog Antagonist) with Concurrent Chemotherapy and Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer.
*1st priority

Previously Treated (Allows 1 prior regimen)

VICCGI0831
An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer
*1st Priority

VICC GI 0804
A Randomized, Phase II Study of Folfox or Folfiri with AG-013736 Or Bevacizumab in Patients with Metastatic Colorectal Cancer After Failure of an Irinotecan or Oxaliplatin-Containing First-Line Regimen
VICCAN
Cool Springs
*2nd Priority
Arms A & B closed; Arms C & D open

KRAS Wild type only

VICC GI 0622
A Phase I/II Clinical and Biological Evaluation of Combined EGFR Blockade with Erlotinib and Cetuximab in Patients with Advanced Cancer (Phase I) or Advanced Colorectal Cancer (Phase II)

Previously Treated Any number prior regimens, but no prior EGFR inhibitors

KRAS Wild type only

VICC GI 0622
A Phase I/II Clinical and Biological Evaluation of Combined EGFR Blockade with Erlotinib and Cetuximab in Patients with Advanced Cancer (Phase I) or Advanced Colorectal Cancer (Phase II)
*1st Priority

Allows any number prior regimens/ Including EGFR Inhibitors

VICC PHI 0725
Phase I Study of KRN Monoclonal Antibody in Patients with Colorectal Cancer

Treatment for Brain Metastasis

VICC RAD 0521
A Phase I Study of Lithium during Whole Brain Radiotherapy For Patients With Brain Metastases

Resectable Colorectal Liver Mets

Trial Pending

KEY

- Pending
- Accrual on hold
- Open

Team Leader Signature and Date _____